儿童急性鼻窦炎阿莫西林-克拉维酸与阿莫西林治疗失败及不良事件比较
该队列研究基于全国医疗利用数据库,纳入17岁及以下新诊断急性鼻窦炎并同日新开具阿莫西林-克拉维酸或阿莫西林处方的儿童和青少年,采用倾向评分匹配比较两种经验性抗生素。匹配后198 942例(每组99 471例),治疗失败总体发生率1.7%,严重失败(急诊或住院)0.01%;两组治疗失败风险无差异(RR 0.98,95%CI 0.92-1.05)。阿莫西林-克拉维酸组胃肠道症状(RR 1.15,95%CI 1.05-1.25)和酵母菌感染(RR 1.33,95%CI 1.16-1.54)风险更高。按年龄分层后,12-17岁组阿莫西林-克拉维酸治疗失败风险RR 0.87(95%CI 0.79-0.95),0-5岁组不良事件风险RR 1.23(95%CI 1.10-1.37)。
要点
- 门诊儿童急性鼻窦炎中,阿莫西林-克拉维酸与阿莫西林治疗失败风险无差异(RR 0.98,95%CI 0.92-1.05)。
- 阿莫西林-克拉维酸胃肠道症状风险更高(RR 1.15,95%CI 1.05-1.25),酵母菌感染风险更高(RR 1.33,95%CI 1.16-1.54)。
- 12-17岁青少年中,阿莫西林-克拉维酸治疗失败风险RR 0.87(95%CI 0.79-0.95)。
- 0-5岁儿童中,阿莫西林-克拉维酸不良事件风险RR 1.23(95%CI 1.10-1.37);6-11岁RR 1.19(95%CI 1.04-1.35)。
- 总体治疗失败率1.7%,严重失败(急诊或住院)仅0.01%。
适用人群与场景
- 17岁及以下儿童和青少年,新门诊诊断急性鼻窦炎,且同日新开具阿莫西林-克拉维酸或阿莫西林处方。
研究设计与关键结果
- 研究类型:队列研究,基于全国医疗利用数据库,采用倾向评分匹配。
- 样本量:匹配前320 141例;匹配后198 942例(每组99 471例),其中女性100 340例(50.4%),12-17岁101 726例(51.1%),6-11岁52 149例(26.2%),0-5岁45 067例(22.7%)。
- 主要终点:治疗失败(新抗生素处方、因急性鼻窦炎急诊或住院、或因鼻窦炎并发症住院的复合终点),评估时间为入组后1-14天;总体发生率1.7%,严重失败(急诊或住院)0.01%。
- 阿莫西林-克拉维酸 vs 阿莫西林治疗失败风险:RR 0.98(95%CI 0.92-1.05),无差异。
- 不良事件:阿莫西林-克拉维酸组胃肠道症状风险更高(RR 1.15,95%CI 1.05-1.25),酵母菌感染风险更高(RR 1.33,95%CI 1.16-1.54)。
- 年龄分层治疗失败风险(阿莫西林-克拉维酸 vs 阿莫西林):0-5岁RR 0.98(95%CI 0.86-1.12);6-11岁RR 1.06(95%CI 0.92-1.21);12-17岁RR 0.87(95%CI 0.79-0.95)。
- 年龄分层不良事件风险(阿莫西林-克拉维酸 vs 阿莫西林):0-5岁RR 1.23(95%CI 1.10-1.37);6-11岁RR 1.19(95%CI 1.04-1.35);12-17岁RR 1.04(95%CI 0.95-1.14)。
证据类型、等级与局限
- 证据类型:队列研究(倾向评分匹配)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现可能有助于急性鼻窦炎经验性抗生素选择的决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acute sinusitis is one of the most common indications for antibiotic prescribing in children, with an estimated 4.9 million such prescriptions in the US annually. Consensus does not exist regarding the optimal empirical antibiotic.
OBJECTIVE: To compare amoxicillin-clavulanate vs amoxicillin for the treatment of acute sinusitis in outpatient children.
DESIGN, SETTING, AND PARTICIPANTS: Cohort study of children and adolescents aged 17 years or younger with a new outpatient diagnosis of acute sinusitis and a same-day new prescription dispensation of amoxicillin-clavulanate or amoxicillin in a nationwide health care utilization database. Propensity score matching was used to mitigate confounding.
EXPOSURE: A new prescription dispensation of amoxicillin-clavulanate or amoxicillin.
MAIN OUTCOMES AND MEASURES: Treatment failure, defined as an aggregate of a new antibiotic dispensation, emergency department or inpatient encounter for acute sinusitis, or inpatient encounter for a sinusitis complication, was assessed 1 to 14 days after cohort enrollment. Adverse events were evaluated, including gastrointestinal symptoms, hypersensitivity and skin reactions, acute kidney injury, and secondary infections.
RESULTS: The cohort included 320 141 patients. After propensity score matching, there were 198 942 patients (99 471 patients per group), including 100 340 (50.4%) who were female, 101 726 (51.1%) adolescents aged 12 to 17 years, 52 149 (26.2%) children aged 6 to 11 years, and 45 067 (22.7%) children aged 0 to 5 years. Treatment failure occurred in 1.7% overall; 0.01% had serious failure (an emergency department or inpatient encounter). There was no difference in the risk of treatment failure between the amoxicillin-clavulanate and amoxicillin groups (relative risk [RR], 0.98 [95% CI, 0.92-1.05]). The risk of gastrointestinal symptoms (RR, 1.15 [95% CI, 1.05-1.25]) and yeast infections (RR, 1.33 [95% CI, 1.16-1.54]) was higher with amoxicillin-clavulanate. After patients were stratified by age, the risk of treatment failure after amoxicillin-clavulanate was an RR of 0.98 (95% CI, 0.86-1.12) for ages 0 to 5 years; RR was 1.06 (95% CI, 0.92-1.21) for 6 to 11 years; and RR was 0.87 (95% CI, 0.79-0.95) for 12 to 17 years. The age-stratified risk of adverse events after amoxicillin-clavulanate was an RR of 1.23 (95% CI, 1.10-1.37) for ages 0 to 5 years; RR was 1.19 (95% CI, 1.04-1.35) for 6 to 11 years; and RR was 1.04 (95% CI, 0.95-1.14) for 12 to 17 years.
CONCLUSIONS AND RELEVANCE: In children with acute sinusitis who were treated as outpatients, there was no difference in the risk of treatment failure between those who received amoxicillin-clavulanate compared with amoxicillin, but amoxicillin-clavulanate was associated with a higher risk of gastrointestinal symptoms and yeast infections. These findings may help inform decisions for empirical antibiotic selection in acute sinusitis.
参考来源
- Savage TJ, Kronman MP, Sreedhara SK, et al. Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis. JAMA. 2023. PMID: 37721610. doi:10.1001/jama.2023.15503
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。